Apply the clinical variables for non-dysplastic Barrett's to visualize the predicted cancer progression risk.
Guidelines & Evidence
Clinical Details
Section 1
When to Use
When to Use
Selecting patients with chronic Gastroesophageal Reflux Disease (GERD) for screening gastroscopy
Identifying high-risk asymptomatic individuals who may harbor Barrett's Oesophagus (BE)
Standardizing the referral pattern for "screening" vs "diagnostic" endoscopy
Philosophy of Screening
Because BE is the only known precursor to esophageal adenocarcinoma (OAC), screening high-risk individuals allows for early detection and intervention before malignant transformation.
Family History of Barrett's or Oesophageal Adenocarcinoma (1st degree relative).
Screening Threshold
The ACG current recommendation is to screen patients with "Chronic GERD PLUS at least 3 of the risk factors" listed above.
Section 3
Pearls/Pitfalls
The Non-GERD Exception
Approximately 40% of patients with Oesophageal Adenocarcinoma (OAC) report NO history of chronic GERD. This is why screening based purely on heartburn is insufficient. High-risk profiles (e.g., Obese smoking males > 60) should be considered for a "once-in-a-lifetime" screening even in the absence of severe symptoms.
Screening Modalities
While Endoscopy (EGD) is the gold standard, non-endoscopic cell-collection devices (e.g., Cytosponge) are emerging as cost-effective alternatives for population screening in low-resource or high-volume settings.
Clinical Pearls
Central obesity (increased waist-to-hip ratio) is a more potent risk factor than simple BMI
H. pylori infection is actually associated with a *reduced* risk of Barrett's and OAC (protective effect on gastric acidity)
Female patients generally have a much lower OAC risk; screening is only recommended in females with multiple high-risk factors (Obesity, Smoking, Fam Hx)
Section 4
Next Steps
Management Action
01
Low Risk: Symptomatic GERD management; No routine screening.
02
High Risk (Screening Recommended): Perform white-light gastroscopy with NBI and 4-quadrant biopsies (Seattle Protocol) every 1–2 cm of any suspected BE segment.
Complementary Tools
Prague C&M Classification
Lyon Consensus on GERD
Siewert Classification (OGJ Location)
Section 5
Evidence Appraisal
ACG Clinical Guideline (2022)
ACG Clinical Guideline for the Diagnosis and Management of Gastroesophageal Reflux Disease.
Katz PO et al. • American Journal of Gastroenterology. 2022;117(1):27-56. The definitive modern screening framework.
Developed based on large-scale epidemiological meta-analyses (like the BEACON consortium) that identified the "Perfect Storm" of demographics and mechanical-reflux variables that precede adenocarcinoma.
